Omar Nadeem / nature - Nature Medicine, Published online: 20 April 2026; doi:10.1038/s41591-026-04365-yAs presented at the 2026 AACR Annual Meeting, in a phase 2 trial, treatment of patients with high-risk smoldering multiple myeloma with BCMA-targeting CAR T cell therapy cilta…
AI Summary: The CAR-PRISM phase 2 study reports that ciltacabtagene autoleucel, a BCMA-directed CAR T therapy, produced meaningful responses in patients with high‑risk smoldering multiple myeloma, suggesting potential to delay progression to symptomatic disease and defer immediate treatment. Early results show promising efficacy with manageable toxicities, hinting at a shift toward treating disease earlier rather than later.
livescience - A kea parrot in New Zealand who lost the top part of his beak when young has developed a new way to fight other males that has made him unbeatable.
AI Summary: Bruce, a parrot missing his upper beak, maintains top social rank by using an inventive "jousting" maneuver during conflicts. Avian behaviorists are both amused and impressed: despite a major physical handicap, Bruce’s behavioral adaptation secures resources and dominance — a tidy lesson in resilience and evolutionary improvisation.
Kathleen Medora / aacr - SAN DIEGO – Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma (ASPS), which primarily affects adolescents and young adults, who received immunotherapy beyond the standard two years, according to results from …
AI Summary: Observational data indicate extended checkpoint inhibitor therapy can be tolerated by patients with alveolar soft part sarcoma and may provide sustained disease control for many. The findings support considering prolonged treatment in select cases, while underscoring the need for vigilant monitoring for late toxicities and randomized trials to confirm benefit.
abcnews - HiPP is recalling some baby food jars in Austria after samples tested positive for rat poison in Austria, Slovakia and the Czech Republic
AI Summary: Austrian health authorities have ordered a recall of specific HiPP baby food jars after lab tests detected contamination with a rodent poison. Retailers pulled the affected batches, parents are being urged to check product codes and discard implicated jars, and investigators are tracing how the contamination occurred while monitoring for any reported illnesses.
livescience - Expect bright fireballs during the Lyrid meteor shower, which will peak in moonless skies on April 22, 2026.
AI Summary: The Lyrid meteor shower reaches its spring peak in moonless skies, giving skywatchers a chance to spot a steady stream of meteors. Best viewing is away from city lights on the peak nights, no telescope required—just patience, a blanket and realistic expectations. It’s nature’s modest, low‑budget fireworks display.
medicalxpress - A landmark trial presented at ESCMID Global 2026 shows that improving oral hygiene for hospital patients can reduce the risk of non-ventilator-associated hospital-acquired pneumonia (NV-HAP) by 60%.
AI Summary: A major randomized trial found that simple improvements in oral care—regular toothbrushing and mouth hygiene—cut hospital‑acquired pneumonia risk by over half in hospitalized patients. The low‑cost intervention reduced respiratory complications and antibiotic use, suggesting wards could prevent serious infections with a toothbrush rather than another headline‑seeking drug.
oncodaily - KRAS G12D has long been one of the most frustrating targets in thoracic oncology. It is biologically important, clearly druggable in theory, and yet patients with KRAS G12D-mutant non-small cell […]
AI Summary: Investigational KRAS(ON) inhibitor zoldonrasib produced effective, durable responses in patients with advanced KRAS G12D–mutated non‑small‑cell lung cancer after prior therapy. Early‑phase data show meaningful tumour shrinkage and a manageable safety profile, offering a targeted option for a mutation long considered untargetable and breathing new life into KRAS drug development.

StackHealth RSS
StackHealth Time Machine
More StackHealth
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.